Comment on "Trends in the incidence of secondary hip fractures and osteoporosis treatment in Japan (FY2012-FY2023)" [0.03%]
对“日本二次髋部骨折发病率及骨质疏松症治疗趋势（2012财年-2023财年）”一文的评论
Huzaifa Khurshid,Munir Ahmad
Huzaifa Khurshid
Response to: "Comment on 'Identification of potential diagnostic and therapeutic apoptosis-related causal targets for osteoporosis: an integrated multi-omics analysis'" [0.03%]
“整合多组学分析鉴定骨质疏松潜在诊断和治疗的凋亡相关因果靶点”的评论回复
Yixi Wang,Lintao Xia,Yang Xiao et al.
Yixi Wang et al.
Comment on "Identification of potential diagnostic and therapeutic apoptosis-related casual targets for osteoporosis: an integrated multi-omics analysis" [0.03%]
关于“整合多组学分析识别潜在的诊断和治疗与凋亡相关的骨质疏松症病因靶点”的评论
Shumeng Huang,Diguang Wen
Shumeng Huang
Response to the Letter to the Editor, Commentary on "Incident subclinical vertebral fractures and health-related quality of life: JPOS cohort study" [0.03%]
关于“JPOS队列研究中偶发椎体亚临床骨折与生活质量关系”的来信及回复
Mayumi Uesaka,Masami Hamada,Takahiro Tachiki et al.
Mayumi Uesaka et al.
Author's response to the letter regarding 'Association of serum magnesium levels and calcimimetic use: fractures and cardiovascular events in Japanese haemodialysis patients' [0.03%]
镁水平与钙敏化剂使用对日本血液透析患者骨折和心血管事件的关联：作者答复
Tomohiro Saito,Masahide Mizobuchi,Kiryu Yoshida et al.
Tomohiro Saito et al.
Toward skeletal phenotyping in magnesium-calcimimetic studies of hemodialysis [0.03%]
镁-钙激动剂在血液透析患者中的骨靶标表型研究展望
Kaiquan Zhang,Meng Zhao,Dongdong Li
Kaiquan Zhang
Response to "Revisiting Inflammaging: A Critical Appraisal of Its Role in Alveolar Bone Loss" [0.03%]
“重新审视炎性衰老：对其在牙槽骨吸收中的作用的批判性评价”的答复
Meircurius Dwi Condro Surboyo,Kridtapat Sirisereephap,Tomoki Maekawa
Meircurius Dwi Condro Surboyo
24-month real-world persistence and compliance of denosumab versus alendronate among postmenopausal women with osteoporosis in Australia, Taiwan, South Korea, Hong Kong, and Singapore [0.03%]
澳大利亚、台湾、韩国、香港和新加坡绝经后妇女的denosumab与阿仑膦酸在治疗骨质疏松症方面的24个月真实世界依从性和持续性研究
Tang Ching Lau,Dong-Gune Chang,Chung-Hwan Chen et al.
Tang Ching Lau et al.
Introduction: To compare 24-month persistence and compliance of denosumab with alendronate in postmenopausal women with osteoporosis across 5 Asia-Pacific territories. ...
Eldecalcitol and calcium supplementation in Chinese women with postmenopausal osteoporosis: a prospective observational cohort study [0.03%]
依达钙维生素D和钙补充剂对中国绝经后妇女骨质疏松症患者的影响：前瞻性观察队列研究
Yan Jiang,Yuhong Zeng,Li Xin et al.
Yan Jiang et al.
Introduction: Eldecalcitol is an active vitamin D3 derivative approved for the treatment of osteoporosis in Japan and postmenopausal osteoporosis in China. However, the impact of concomitant calcium supplementation on its...